Zeng, Ziqing
Li, Liqiang
Tao, Jinping
Liu, Jiayue
Li, Hongjun
Qian, Xueming
Yang, Zhi http://orcid.org/0000-0003-2084-5193
Zhu, Hua http://orcid.org/0000-0002-4198-5809
Funding for this research was provided by:
National Natural Science Foundation of China projects (No. 82203612, 82171973, 82171980, 82102092 and 82172604)
Capital’s Funds for Health Improvement and Research (No. 2022-2Z-2154 and 2022-2Z-2155)
Article History
Received: 29 August 2023
Accepted: 1 December 2023
First Online: 8 December 2023
Declarations
:
: Intellectual properties protection have been filed by Suzhou Transcenta Therapeutics Co., Ltd., inventor of Xueming Qian; Hongjun Li, and Beijing Cancer Hospital, inventor of Hua Zhu; Yang Zhi. All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: The manuscript is approved by all authors for publication.
: All animal experiments were approved by the Peking University Cancer Hospital Animal Care and Use Committee (reference number: EAEC 2022-01).